ACTRN12624000735550尚未招募Unknown
A Prospective, Single-arm, Open-label, Interventional, Pilot Study to Evaluate the Efficacy and Safety of a Novel Continuous Glucose Monitoring System in Children and Adult Participants with Type 1 and Type 2 Diabetes
适应症
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
- i-SENS, Inc.
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 7 Years 至 o limit（—）
- 性别
- All
入选标准
- •1.Children and adolescents who are 7 to 17 years of age (inclusive).
- •2.Adults who are 18 years of age or older.
- •3.Participants with type 1 diabetes, or with type 2 diabetes and on more than one anti-diabetic medication.
- •4.Participants who voluntarily decide to participate in the study and provide written informed consent.
排除标准
- •1.Potential participants older than = 45 years with more than 2 further cardiovascular risk factors (see factors a-c below) will be excluded from study entry:
- •a.)Current Smoker.
- •b.)hypertension (>150 / 80 mmHg).
- •c.)HbA1c > 9.0 %.
- •2.Participants with the following uncontrolled abnormal skin/skin diseases at the CGM sensor attachment sites including but not limited to:
- •Severe psoriasis, recent burn injury or severe sunburn, severe eczema, severe scar, extensive tattoo, dermatitis herpetiformis, severe rash and Staphylococcus aureus infection.
- •3.Participants with moderate/severe allergic contact dermatitis to medical adhesives.
- •4.Participants with severe hypoglycemia events within 6 months prior to screening. Severe hypoglycemia refer to loss of consciousness or seizure requiring emergency medical treatment due to hypoglycemia
- •5.Participants with >1 episode of diabetic ketoacidosis within the past 6 months prior to screening.
- •6.Participants with cerebrovascular diseases or the following cardiovascular diseases (but not limited to) when instable (defined by event or increasing symptoms in the last 6 months) or with insufficient therapy including but not limited to:
- •Ischemic heart disease, peripheral vascular disease, cardiomyopathy, congenital heart disease and serious arrhythmia.
- •7.Diagnosis of epilepsy or adrenal disorders, or episode/s of syncope within 6 months prior to screening.
- •8.Participants with chronic infectious disease.
- •9.Participants with anemia (hemoglobin below laboratory-determined normal range for age and sex).
- •10.Participants scheduled for unchangeable X-ray, Magnetic resonance imaging, or computed tomography scan during the study.
- •11.Pregnant or lactating women. Urine pregnancy test screening to be conducted on all pre-menopausal women.
- •12.Participants who are currently participating or participated within 2 weeks before screening in another study or plan to participate in another study that in the opinion of the investigator would affect the safety of the study participant or the study results.
- •13.Participants unwilling to abstain from use of nutritional supplements containing xylose.
- •14.Participants with cognitive impairment or who are not suitable for this study or may be at increased risk associated with study participation in the opinion of the investigator.
- •15.Wearing of a pacemaker or other comparable medical devices.
- •16.Employees or family members of the sponsor or the clinical investigator.
- •17.History of frequent catheter abscesses associated with pump therapy.
研究者
相似试验
已完成
不适用
Evaluation of the efficacy and safety of a new Continuous Glucose Monitoring System in adult patients with type 1 and type 2 diabetesType 2 DiabetesType 1 DiabetesACTRN12622000290796i-SENS, Inc.69
已完成
不适用
A prospective, single arm, open-label, interventional, pivotal study to evaluate the efficacy and safety of the Continuous Glucose Monitoring System ‘CareSens Air’ in adult patients with type 1 and type 2 diabetesE14Unspecified diabetes mellitusDRKS00028739i-SENS, Inc.50
尚未招募
Unknown
To Study safety and effectiveness of the Device used to deliver medicines and fluids through the long bones instead of intravenous routeCTRI/2023/04/051760RCupe Lifesciences Private Limited
招募中
2 期
Romiplostim in Inherited marrow failure syndromes - Safety and EfficacyCTRI/2024/03/063966INDIAN COUNCIL OF MEDICAL RESEARCH
进行中（未招募）
1 期
Open-label, single arm, interventional study to explore the efficacy and safety of paliperidone ER in the management of patients with acute agitation and/or aggression - IMPACTEUCTR2009-015629-35-BEJanssen-Cilag NV/SA